"Moderna Investor's Massive 3,000% Profit from Small Biotech Investment"

Noubar Afeyan, the billionaire backer of Moderna Inc., is set to make a significant gain on another biotech investment as Sigilon Therapeutics Inc., in which his venture capital firm owns a stake, saw its value quintuple after Eli Lilly agreed to acquire the company. Afeyan's firm could potentially receive a windfall of $101 million if Sigilon meets certain benchmarks, including regulatory approval of a specified product. While the hurdles are high, investors are optimistic as the stock's closing price exceeded Lilly's initial payment. Afeyan, who holds more than 100 patents and has been involved in building over 70 startups, has become a billionaire through his investments in the life sciences industry.